8-K: Citius Oncology Receives Nasdaq Deficiency Notice

Citius Oncology has been notified by Nasdaq that its common stock has fallen below the minimum $1.00 bid price requirement for continued listing.

Summary

• Citius Oncology received a formal notice from Nasdaq on April 22, 2026, regarding non-compliance with the minimum $1.00 bid price rule.
• The company's stock closed below the $1.00 threshold for 30 consecutive business days.
• The company has been granted an initial 180-day compliance period ending October 19, 2026.
• Compliance can be regained if the stock price closes at or above $1.00 for at least ten consecutive business days before the deadline.
• The current listing status remains unchanged, and the stock continues to trade under the symbol CTOR.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as it highlights downward pressure on the stock price and introduces the risk of delisting or the need for dilutive/structural corporate actions.

Positives

• The company has a clear 180-day window to address the deficiency without immediate threat of delisting.
• There is a potential for a second 180-day extension if specific market value requirements are met.

Negatives

• The company is currently failing to meet Nasdaq's minimum bid price requirement.
• There is no guarantee that the company will be able to regain compliance within the allotted timeframe.
• The potential need for a reverse stock split is explicitly mentioned as a possible path to compliance.

Risks

• Risk of delisting from the Nasdaq Capital Market if the bid price does not recover.
• Potential negative impact on investor sentiment and stock liquidity due to the deficiency notice.
• Possible requirement to execute a reverse stock split, which may be viewed negatively by shareholders.

Future Outlook

The company is currently evaluating options to regain compliance with the Nasdaq Bid Price Rule, which may include a reverse stock split if necessary.

Industry Context

StockSavvy.ai notes that receiving a Nasdaq deficiency notice is a common challenge for small-cap biotech firms facing market volatility, often necessitating strategic corporate actions to maintain exchange eligibility.

Comparison to Industry Standards

• The 180-day compliance period is standard procedure for Nasdaq-listed companies failing to meet minimum bid price requirements.
• Many small-cap biotechnology companies utilize reverse stock splits as a standard mechanism to regain compliance when organic price appreciation is insufficient.

Stakeholder Impact

• Shareholders face uncertainty regarding the future listing status of the stock.
• Potential for increased volatility as the compliance deadline approaches.

Next Steps

• Monitor stock price performance to determine if organic compliance is achievable.
• Evaluate the necessity of a reverse stock split to meet listing requirements before the October 19, 2026 deadline.

Key Dates

Recommendation

Investors should hold until the company clarifies its strategy for regaining compliance, as the risk of a reverse stock split or potential delisting creates significant uncertainty.

Keywords

Citius Oncology, Nasdaq, Delisting, Bid Price Rule, CTOR, Compliance